French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). | French ...

Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer ...

Last month, the NIH announced that it had found evidence of research misconduct by Eliez | This week on "The Top Line," we ...

Omega Therapeutics is halting work on its only clinical-stage candidate as part of a strategic refocus centered on three ...

Philips has secured an FDA clearance for what it describes as the world’s first imager to combine spectral CT with ...

Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its ...

Gene therapy for some diseases, including Duchenne muscular dystrophy (DMD), can be tricky because the needed gene is often ...

Caris Life Sciences has obtained an FDA approval for its MI Cancer Seek tumor profiling assay, unlocking its use as a ...

The two companies have been working together since 2017, and, in 2021, they agreed to collaborate on NM26, a bispecific ...

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...

Since the 2023 financing round, Flare’s lead program FX-909 has moved into a phase 1 clinical trial for patients with ...

Bristol Myers Squibb has linked its CD19-directed CAR-T cell therapy to sustained clinical responses in people with systemic ...